Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inqovi as Maintenance Therapy Post-Transplant for Myeloid Neoplasms
NCT04980404Phase 1Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of inqovi in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Recommended Phase 2 Schedule Dose at 42 days. Started Sep 2021; status: active, not recruiting.
02
Drugs
inqovi
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT04980404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04980404.